Short answer
XOMA Royalty Corp (XOMA) filed its Q3 2025 10-Q quarterly report on Nov 12, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $9M (up 29.9% year over year) with net income of $14M.
Q3 2025 key financials · XBRL
- Revenue
- $9M
- +29.9% YoY · −28.8% QoQ
- Net income
- $14M
- +181.5% YoY · +52.9% QoQ
- Operating margin
- -14.2%
- EPS (diluted)
- $0.70
- +147.6% YoY · +59.1% QoQ
Source: XBRL data from the XOMA Royalty Corp (XOMA) Q3 2025 10-Q on SEC EDGAR. USD.
XOMA Royalty Corp Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue, YoY change, profitability margins, segment performance, and cash-flow figures not provided
- Outlook references potential VABYSMO and OJEMDA income, acquisitions, royalties, and milestone payments
- Headwinds include regulatory uncertainty, development funding needs, competition, macroeconomic conditions, tariffs, and high interest rates
Risk Factors
- New tariff risk triggered by U.S. tariff announcements, including potential up to 100% pharmaceutical tariffs
- Regulatory disruption risk from federal workforce layoffs and U.S. government shutdown beginning October 2025
- FDA review delays from agency funding, staffing, leadership, and policy uncertainty
- Market downturn risk from tariffs, geopolitical conflict, inflation, and high interest rates
- Liquidity risk from reduced ability to raise funds during market downturns
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other XOMA Royalty Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.